Business context and reporting period
Novus Therapeutics, Inc. filed this unaudited Form 10-Q for the quarter ended March 31, 2018. It is an early-stage specialty pharmaceutical company developing treatments for ear, nose and throat disorders. Its lead candidate, OP-02, targets otitis media; OP-01 is a foam-based drug-delivery platform whose development was paused. The filing’s registrant is Novus Therapeutics, Inc., not Eledon Pharmaceuticals, Inc.; investors should verify the company and filing identification.
Key financial results and position
| Metric | Q1 2018 | Q1 2017 |
|---|---|---|
| Revenue | None reported | None reported |
| Research and development expense | $1.097 million | $0.479 million |
| General and administrative expense | $1.698 million | $0.906 million |
| Total operating expenses | $2.795 million | $1.385 million |
| Net loss | $2.806 million | $1.374 million |
| Net loss per share, basic and diluted | $0.36 | $0.59 |
| Cash used in operating activities | $2.271 million | $0.882 million |
At March 31, 2018, cash was $22.523 million, working capital was $22.4 million, total assets were $25.917 million, and total liabilities were $1.619 million. No debt balance is reported. Cash increased by $5.220 million during the quarter, primarily because of $7.491 million in net equity proceeds, partly offset by operating cash use. The company reported an accumulated deficit of $30.312 million. No operating margin is meaningful because the company had no revenue.
Changes versus the prior comparable period
- Operating expenses rose 102% to $2.795 million, and net loss increased by $1.432 million. R&D expense more than doubled, mainly reflecting increased OP-02 development spending.
- G&A expense rose 87%, primarily from public-company administrative costs, higher stock-based compensation and legal costs, partly offset by lower merger-related expenses.
- Cash used in operations increased to $2.271 million from $0.882 million. The company received no financing proceeds in Q1 2017, compared with $7.491 million net from its equity distribution program in Q1 2018.
- Reported 2017 results may not be directly comparable: the May 2017 reverse merger changed the operating business. The filing presents pro forma combined Q1 2017 net loss of $3.630 million, versus reported net loss of $1.374 million.
Outlook, risks and unusual items
- Management expected cash resources to fund operations for at least 12 months from issuance of the financial statements and concluded substantial doubt about going concern did not exist. It expects continued losses and anticipates R&D expense will rise as OP-02 advances.
- Novus expected to start an OP-02 Phase 1 program in 2018, conditional on completing formulation development and producing a clinical-grade cGMP batch. The candidate had not yet entered human clinical studies. OP-01 remained paused.
- The company may need additional financing to complete development; funding may be unavailable or dilutive. Failure to obtain funding could require delays, spending cuts or suspension of programs.
- Material development risks include clinical, regulatory and manufacturing uncertainty; dependence on third-party suppliers and contractors; and the possibility that early trial results will not predict later outcomes. No product candidate had regulatory approval.
- Tokai-related securities litigation remained unresolved in several proceedings; the company said it could not estimate a reasonably possible loss range and had not accrued a liability. Two federal actions were dismissed without prejudice in May 2018; other proceedings remained pending. The filing reported no contingent liabilities requiring accrual at March 31.
- The company sold 2,463,966 shares through its equity distribution agreement for approximately $8.5 million gross proceeds through March 9, 2018; no further sales under that agreement were planned. Common shares outstanding were 9,407,024 at March 31.
Important facts for investors to verify
- Confirm the issuer: this filing is for Novus Therapeutics, Inc., despite the request identifying Eledon Pharmaceuticals, Inc.
- Check whether OP-02 formulation and cGMP manufacturing milestones were completed and whether the planned Phase 1 program began.
- Assess cash burn, financing needs and runway against current development plans; the stated 12-month runway was measured from the 2018 filing issuance date.
- Review subsequent developments in the Tokai-related litigation and any resulting financial exposure.
- Account for the reverse merger when comparing periods, including the filing’s pro forma 2017 results and the substantial increase in shares outstanding.